Suppr超能文献

非精原细胞性生殖细胞肿瘤晚期复发的特征与管理

Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour.

作者信息

Jay Alexander P M, Aldiwani Mohammed, O'Callaghan Michael E, Pearce Adam K, Huddart Robert A, Mayer Erik, Reid Alison H, Nicol David L

机构信息

Department of Urology, Royal Marsden Hospital, London, UK.

Urology Unit, Flinders Medical Centre, Adelaide, Australia.

出版信息

Eur Urol Open Sci. 2021 Jun 7;29:82-88. doi: 10.1016/j.euros.2021.04.008. eCollection 2021 Jul.

Abstract

BACKGROUND

Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr.

OBJECTIVE

To review features of NSGCT LR in a UK tertiary centre.

DESIGN SETTING AND PARTICIPANTS

A total of 3064 patients were referred from January 2005 to December 2017. We identified patients who experienced LR after initial pathology demonstrated NSGCT and reviewed data for their original and LR presentation and management.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Outcomes included time to LR measured from the date of diagnosis, and overall survival.  This was assessed using  Cox proportional Hazards modelling, with stratification or adjustment for potential confounders.

RESULTS AND LIMITATIONS

We identified 101 patients with LR; the median time to LR was 96 mo. Forty-three patients (42.6%) experienced relapse after 10 yr. Univariable log-rank testing revealed that the median time to LR was significantly shorter for patients who had not received induction chemotherapy (iCTx; 54 mo, 95% confidence interval [CI] 48-108) than for those who did (112 mo, 95% CI 84-186;  = 0.04). Patients who had received iCTx were less likely to have elevated tumour markers (36% vs 46%) and more likely to undergo initial surgical resection at LR compared to CTx-naïve patients. Postpubertal teratoma (PPT), yolk sac, and dedifferentiated elements predominated for patients with iCTx exposure, whereas active GCT or fibrosis predominated in postchemotherapy resections for CTx-naïve patients at LR. Forty-one men underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) as part of their initial treatment for metastatic disease. Of these, 20 experienced LR in the retroperitoneum, with 18 undergoing repeat RPLND as part of their LR management. Fifteen of the repeat RPLND histopathology specimens had a PPT component. There have been 23 deaths overall; survival was worse for patients presenting with symptoms (13/36, 33%) and those receiving CTx and no surgery (10/17, 59%) at LR.

CONCLUSIONS

When LR of NSGCT occurs, it is frequently after an extended interval and is later among patients with prior iCTx, with PPT predominating. The high frequency of LR within the retroperitoneum following PC-RPLND reinforces the need for good-quality PC-RPLND.

PATIENT SUMMARY

We reviewed data for patients who had a late relapse of testicular cancer. We found that patients who did not receive chemotherapy as the first treatment for their initial diagnosis had a shorter time to relapse. Our results highlight the importance of long-term follow-up for testicular cancer.

摘要

背景

非精原细胞瘤性生殖细胞肿瘤(NSGCT)的晚期复发(LR)并不常见,发表的数据有限。LR被定义为在无病间隔2年后发生的复发。

目的

回顾英国一家三级中心NSGCT-LR的特征。

设计、设置和参与者:2005年1月至2017年12月共转诊3064例患者。我们确定了那些在初始病理显示为NSGCT后经历LR的患者,并回顾了他们初始和LR表现及治疗的数据。

结果测量和统计分析

结果包括从诊断日期开始测量的LR时间和总生存期。使用Cox比例风险模型进行评估,并对潜在混杂因素进行分层或调整。

结果与局限性

我们确定了101例LR患者;LR的中位时间为96个月。43例患者(42.6%)在10年后复发。单变量对数秩检验显示,未接受诱导化疗(iCTx)的患者LR的中位时间(54个月,95%置信区间[CI]48-108)显著短于接受诱导化疗的患者(112个月,95%CI 84-186;P = 0.04)。与未接受过CTx的患者相比,接受iCTx的患者肿瘤标志物升高的可能性较小(36%对46%),在LR时更有可能接受初始手术切除。青春期后畸胎瘤(PPT)、卵黄囊和去分化成分在接受iCTx的患者中占主导,而在LR时未接受过CTx的患者化疗后切除标本中活性生殖细胞肿瘤或纤维化占主导。41名男性在初始治疗转移性疾病时接受了化疗后腹膜后淋巴结清扫术(PC-RPLND)。其中,20例在腹膜后复发,18例在LR治疗时接受了重复RPLND。15例重复RPLND组织病理学标本有PPT成分。总体共有23例死亡;LR时出现症状的患者(13/36,33%)和接受CTx且未手术的患者(10/17,59%)生存率较差。

结论

当NSGCT发生LR时,通常是在较长间隔后,且在先前接受过iCTx的患者中较晚出现,以PPT为主。PC-RPLND后腹膜后LR的高发生率强化了高质量PC-RPLND的必要性。

患者总结

我们回顾了睾丸癌晚期复发患者的数据。我们发现,初始诊断时未接受化疗作为首次治疗的患者复发时间较短。我们的结果强调了睾丸癌长期随访的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9063/8317789/5b7cda5d83d4/gr1.jpg

相似文献

1
Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour.
Eur Urol Open Sci. 2021 Jun 7;29:82-88. doi: 10.1016/j.euros.2021.04.008. eCollection 2021 Jul.
4
Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
Eur Urol Oncol. 2021 Apr;4(2):289-296. doi: 10.1016/j.euo.2020.08.007. Epub 2020 Sep 6.
5
Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Eur Urol. 2009 Jan;55(1):217-24. doi: 10.1016/j.eururo.2008.09.027. Epub 2008 Sep 24.
7
Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.
Ther Adv Urol. 2012 Aug;4(4):187-205. doi: 10.1177/1756287212443170.
10
Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Oncol Res Treat. 2018;41(6):370-378. doi: 10.1159/000489508. Epub 2018 May 17.

引用本文的文献

1
Management of Late Relapses in Metastatic Testicular Germ Cell Tumors: Still a Challenge.
Eur Urol Open Sci. 2021 Jun 16;30:11-12. doi: 10.1016/j.euros.2021.05.010. eCollection 2021 Aug.

本文引用的文献

1
Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.
Adv Urol. 2018 Apr 2;2018:8781698. doi: 10.1155/2018/8781698. eCollection 2018.
2
Temporal trends in management and outcomes of testicular cancer: A population-based study.
Cancer. 2018 Jul 1;124(13):2724-2732. doi: 10.1002/cncr.31390. Epub 2018 Apr 16.
3
Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study.
BJU Int. 2017 Jan;119(1):91-99. doi: 10.1111/bju.13569. Epub 2016 Jul 30.
4
Late Relapses in Stage I Testicular Cancer Patients on Surveillance.
Eur Urol. 2016 Aug;70(2):365-71. doi: 10.1016/j.eururo.2016.03.016. Epub 2016 Mar 17.
6
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.
J Clin Oncol. 2015 Jan 1;33(1):51-7. doi: 10.1200/JCO.2014.56.2116. Epub 2014 Aug 18.
7
Germ cell tumour: late recurrence after 43 years.
Ann R Coll Surg Engl. 2011 Jul;93(5):e24-6. doi: 10.1308/147870811X580442.
8
Clinical outcome and predictors of survival in late relapse of germ cell tumor.
J Clin Oncol. 2008 Dec 1;26(34):5524-9. doi: 10.1200/JCO.2007.15.7453. Epub 2008 Oct 20.
9
Treatment of a population based sample of men diagnosed with testicular cancer in the United States.
Urol Oncol. 2009 Nov-Dec;27(6):604-10. doi: 10.1016/j.urolonc.2008.06.004. Epub 2008 Sep 16.
10
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
J Clin Oncol. 2005 Oct 1;23(28):6999-7004. doi: 10.1200/JCO.2005.21.956.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验